pyrroles has been researched along with thromboplastin in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (73.33) | 29.6817 |
| 2010's | 4 (26.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barsotti, A; Brunelli, C; Ghigliotti, G; Leslie, S; Olivotti, L; Rossettin, P; Spallarossa, P | 1 |
| Arbustini, E; Camera, M; Cofrancesco, E; Cortellaro, M; Gabrielli, L; Negri, A; Rossi, F; Tremoli, E | 1 |
| Banas, B; Bangen, P; Dohle, F; Heidenreich, S; Lang, D; Pauels, HG; Terstesse, M | 1 |
| Bellia, A; Carnevale, R; Ferro, D; Lauro, R; Lenti, L; Pignatelli, P; Sanguigni, V; Sorge, R; Tesauro, M; Violi, F | 1 |
| Bartok, A; Huber, K; Jetzl, A; Kopp, CW; Minar, E; Seidinger, D; Stefenelli, T; Steiner, S | 1 |
| du Manoir, J; Francia, G; Hicklin, DJ; Kerbel, RS; Ma, L; Rak, J; Viloria-Petit, A | 1 |
| Chopp, M; Kapke, A; Liu, XS; Lu, M; Morris, DC; Zhang, L; Zhang, ZG | 1 |
| Avcu, F; Ural, AU | 1 |
| Cai, YC; Fang, Y; Li, JQ; Li, P; Li, QZ; Wu, LR; Zhao, SP | 1 |
| Bohrer, A; Dietzen, DJ; Page, KL; Tetzloff, TA; Turk, J | 1 |
| Amato, M; Arquati, M; Baldassarre, D; Brusoni, B; Camera, M; Cortellaro, M; Fiorentini, C; Montorsi, P; Porta, B; Romano, S; Tremoli, E | 1 |
| Adamson, U; Antovic, A; Henriksson, P; Jörneskog, G; Lins, PE; Mobarrez, F; Santesson, P; Tehrani, S; Wallén, NH | 1 |
| Doi, M; Fukushima, H; Hamada, M; Matsui, H; Mizuno, T; Nishio, K; Shida, Y; Shima, M; Sugimoto, M; Yoshioka, A | 1 |
| Antovic, A; Antovic, J; Bröijersen, A; Egberg, N; He, S; Jörneskog, G; Mobarrez, F; Wallén, H; Wiklund, B | 1 |
| Antovic, J; Bröijersen, A; Egberg, N; Jörneskog, G; Mobarrez, F; Wallén, H | 1 |
7 trial(s) available for pyrroles and thromboplastin
| Article | Year |
|---|---|
High doses of atorvastatin do not affect activity of prothrombinase in patients with acute coronary syndromes.
Topics: Acute Disease; Aged; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Female; Fibrinogen; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Platelet Aggregation; Pyrroles; Thromboplastin; Thrombosis | 2002 |
Atorvastatin and thrombogenicity of the carotid atherosclerotic plaque: the ATROCAP study.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Carotid Artery Diseases; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lipoproteins; Macrophages; Male; Middle Aged; Prospective Studies; Pyrroles; Thromboplastin; Thrombosis | 2002 |
Short-term treatment with atorvastatin reduces platelet CD40 ligand and thrombin generation in hypercholesterolemic patients.
Topics: Adenosine Diphosphate; Atorvastatin; Biomarkers; Blood Coagulation; Blood Platelets; CD40 Ligand; Collagen; Coronary Disease; Female; Fibrinolytic Agents; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Monocytes; Multifactorial Inheritance; Peptide Fragments; Prothrombin; Pyrroles; Solubility; Thrombin; Thromboplastin; Treatment Outcome | 2005 |
Atorvastatin reduces thrombin generation after percutaneous coronary intervention independent of soluble tissue factor.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Atorvastatin; Cohort Studies; Coronary Disease; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heptanoic Acids; Humans; Lipids; Lipoproteins; Male; Middle Aged; Prothrombin; Pyrroles; Thrombin; Thromboplastin; Treatment Outcome | 2005 |
Atorvastatin has antithrombotic effects in patients with type 1 diabetes and dyslipidemia.
Topics: Adult; Aged; Atorvastatin; Biomarkers; Blood Platelets; C-Reactive Protein; Cell-Derived Microparticles; Cross-Over Studies; Diabetes Mellitus, Type 1; Double-Blind Method; Dyslipidemias; Fibrin; Fibrinolytic Agents; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Integrin beta3; Middle Aged; P-Selectin; Plasminogen Activator Inhibitor 1; Pyrroles; Sweden; Thrombin; Thromboplastin; Thrombosis; Time Factors; Treatment Outcome | 2010 |
Atorvastatin reduces thrombin generation and expression of tissue factor, P-selectin and GPIIIa on platelet-derived microparticles in patients with peripheral arterial occlusive disease.
Topics: Aged; Atorvastatin; Blood Platelets; Cell-Derived Microparticles; Cross-Over Studies; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Integrin beta3; Male; Middle Aged; P-Selectin; Peripheral Arterial Disease; Pyrroles; Thrombin; Thromboplastin | 2011 |
Release of endothelial microparticles in vivo during atorvastatin treatment; a randomized double-blind placebo-controlled study.
Topics: Aged; Antigens, CD; Atorvastatin; Biomarkers; Cadherins; Cell-Derived Microparticles; Cross-Over Studies; Double-Blind Method; Endothelial Cells; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Peripheral Arterial Disease; Placebos; Pyrroles; Sweden; Thromboplastin; Time Factors; Treatment Outcome | 2012 |
8 other study(ies) available for pyrroles and thromboplastin
| Article | Year |
|---|---|
Protein kinase C (PKC) dependent induction of tissue factor (TF) by mesangial cells in response to inflammatory mediators and release during apoptosis.
Topics: Apoptosis; Calcium; Carbazoles; Cell Line; Cells, Cultured; Chelating Agents; Cyclic AMP-Dependent Protein Kinases; Dose-Response Relationship, Drug; Egtazic Acid; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Gene Expression Regulation; Glomerular Mesangium; Humans; Hydrogen Peroxide; Indoles; Inflammation Mediators; Interleukin-1; Lipopolysaccharides; Naphthalenes; Protein Kinase C; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thromboplastin; Time Factors; Tumor Necrosis Factor-alpha | 2002 |
In vitro procoagulant activity induced in endothelial cells by chemotherapy and antiangiogenic drug combinations: modulation by lower-dose chemotherapy.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Blood Coagulation; Cells, Cultured; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Endothelial Cells; Gemcitabine; Humans; Indoles; Oxindoles; Piperidines; Propionates; Pyrroles; Quinazolines; Thromboplastin | 2005 |
Atorvastatin downregulates tissue plasminogen activator-aggravated genes mediating coagulation and vascular permeability in single cerebral endothelial cells captured by laser microdissection.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Blood Coagulation; Brain; Brain Ischemia; Capillary Permeability; Down-Regulation; Endothelial Cells; Gene Expression; Heptanoic Acids; Humans; Lasers; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Microdissection; Pyrroles; Rats; Rats, Wistar; Receptor, PAR-1; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thromboplastin; Tissue Plasminogen Activator | 2006 |
HMG-CoA reductase inhibitors may affect thrombin generation by reducing factor VII activity in hyperlipidemic patients.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Atorvastatin; Cohort Studies; Coronary Disease; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Lipoproteins; Male; Middle Aged; Prothrombin; Pyrroles; Thrombin; Thromboplastin; Treatment Outcome | 2006 |
Atorvastatin reduces tissue factor expression in adipose tissue of atherosclerotic rabbits.
Topics: Animals; Atherosclerosis; Atorvastatin; Heptanoic Acids; Male; Pyrroles; Rabbits; Subcutaneous Fat; Thromboplastin | 2007 |
Inhibition of 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase blunts factor VIIa/tissue factor and prothrombinase activities via effects on membrane phosphatidylserine.
Topics: Animals; Atorvastatin; Blotting, Western; Cattle; Cells, Cultured; Electrophoresis, Polyacrylamide Gel; Enzyme-Linked Immunosorbent Assay; Factor VIIa; Fibroblasts; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Phosphatidylserines; Pyrroles; Sensitivity and Specificity; Thromboplastin | 2007 |
E-selectin and TFPI are associated with carotid intima-media thickness in stable IHD patients: the baseline findings of the MIAMI study.
Topics: Atorvastatin; Biomarkers; C-Reactive Protein; Carotid Artery Diseases; Cholesterol; E-Selectin; Endothelium, Vascular; Female; Fibrinogen; Heptanoic Acids; Humans; Inflammation; Intercellular Adhesion Molecule-1; Interleukin-6; Interleukin-8; Lipoproteins; Male; Middle Aged; Prospective Studies; Pyrroles; Thromboplastin; Triglycerides; Tumor Necrosis Factor-alpha; Tunica Intima; Vascular Cell Adhesion Molecule-1; von Willebrand Factor | 2008 |
Antithrombotic properties of pravastatin reducing intra-thrombus fibrin deposition under high shear blood flow conditions.
Topics: Atorvastatin; Blood Platelets; Dose-Response Relationship, Drug; Fibrin; Fibrinolytic Agents; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mevalonic Acid; P-Selectin; Perfusion; Platelet Adhesiveness; Platelet Aggregation; Platelet Aggregation Inhibitors; Pravastatin; Pyrroles; Regional Blood Flow; Stress, Mechanical; Thrombin; Thromboplastin; Thrombosis; Time Factors; von Willebrand Factor | 2011 |